Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer
- 1 April 2017
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 130, 21-33
Abstract
No abstract availableKeywords
Funding Information
- NCI (5 P01 CA171983)
This publication has 75 references indexed in Scilit:
- Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999Blood, 2010
- The “Specific” P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)ACS Chemical Neuroscience, 2010
- Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthaseJournal of Lipid Research, 2010
- Mechanisms associated with mitochondrial-generated reactive oxygen species in cancerThis article is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease.Canadian Journal of Physiology and Pharmacology, 2010
- Ceramide and ceramide 1-phosphate in health and diseaseLipids in Health and Disease, 2010
- Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)BMC Cancer, 2008
- Roles of Bioactive Sphingolipids in Cancer Biology and Therapeutics2008
- Sphingolipids and cell deathApoptosis, 2007
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959